Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: rituximabDrug: CHOP regimenDrug: cyclophosphamideDrug: carmustineDrug: doxorubicin hydrochlorideDrug: prednisoneDrug: vincristine sulfateDrug: etoposideProcedure: bone marrow ablation with stem cell supportProcedure: peripheral blood stem cell transplantationRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 397
- Registration Number
- NCT00004031
- Locations
- 🇨🇦
Moncton Hospital, Moncton, New Brunswick, Canada
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
🇨🇦Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
- Conditions
- Lung Cancer
- Interventions
- Biological: filgrastimDrug: carboplatinDrug: etoposideDrug: paclitaxelDrug: topotecan hydrochlorideRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 65
- Registration Number
- NCT00033696
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
🇺🇸University of Massachusetts Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
Combination Chemotherapy in Treating Children With Neuroblastoma
- Conditions
- Neuroblastoma
- Interventions
- Biological: filgrastimBiological: sargramostimDrug: carboplatinDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: etoposideProcedure: conventional surgeryProcedure: neoadjuvant therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 573
- Registration Number
- NCT00003093
- Locations
- 🇺🇸
Columbus Children's Hospital, Columbus, Ohio, United States
🇺🇸Cancer Research Center of Hawaii, Honolulu, Hawaii, United States
🇺🇸MBCCOP - Hawaii, Honolulu, Hawaii, United States
TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma
- Conditions
- LeukemiaLymphoma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1148
- Registration Number
- NCT00002757
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇬🇧Children's Hospital - Sheffield, Sheffield, England, United Kingdom
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 87
- Registration Number
- NCT00005987
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
- Conditions
- LeukemiaLymphoma
- Interventions
- Biological: dactinomycinBiological: sargramostimDrug: carmustineDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: doxorubicin hydrochlorideDrug: methotrexateDrug: etoposideDrug: mercaptopurineDrug: prednisoneDrug: mitoxantrone hydrochlorideDrug: pegaspargaseDrug: vincristine sulfateRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 170
- Registration Number
- NCT00002766
- Locations
- 🇺🇸
Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: bleomycin sulfateBiological: filgrastimDrug: ABVD regimenDrug: dacarbazineBiological: pegfilgrastimDrug: doxorubicin hydrochlorideDrug: BEACOPP regimenDrug: vinblastine sulfateDrug: cyclophosphamideDrug: etoposideDrug: prednisoneDrug: procarbazine hydrochlorideDrug: vincristine sulfate
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Target Recruit Count
- 552
- Registration Number
- NCT00049595
- Locations
- 🇳🇱
Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
🇧🇪Clinique Universitaire De Mont-Godinne, Yvoir, Belgium
🇦🇺Canberra Hospital, Garran, Australian Capital Territory, Australia
Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: Bleomycin sulfateDrug: Stanford V regimenDrug: Doxorubicin hydrochlorideDrug: EtoposideDrug: Mechlorethamine hydrochlorideDrug: PrednisoneDrug: VinblastineDrug: Vincristine sulfate
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 50
- Registration Number
- NCT00002715
- Locations
- 🇺🇸
Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States
Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors
- Conditions
- Brain and Central Nervous System TumorsPediatric Germ Cell TumorExtragonadal Germ Cell Tumor
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-03-15
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT00002472
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 179
- Registration Number
- NCT00003650
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.